Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4Δ30-4995 in Healthy Adult Volunteers

rDEN4Δ30-4995 is a live attenuated dengue virus type 4 (DENV4) vaccine candidate specifically designed as a further attenuated derivative of the rDEN4Δ30 parent virus. In a previous study, 5 of 20 vaccinees who received 10(5) plaque-forming units (PFU) of rDEN4Δ30 developed a transient elevation of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wright, Peter F., Durbin, Anna P., Whitehead, Stephen S., Ikizler, Mine R., Henderson, Susan, Blaney, Joseph E., Thumar, Bhavin, Ankrah, Sharon, Rock, Michael T., McKinney, Brett A., Murphy, Brian R., Schmidt, Alexander C.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2829759/
https://ncbi.nlm.nih.gov/pubmed/19861619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4269/ajtmh.2009.09-0131
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars